Improving Pharmacy Management to Combat Counterfeit and Substandard Drugs

What is it about?

The study assessed the challenges in managing pharmacy business operations with a focus on addressing issues related to counterfeit, substandard, spurious, and adulterated (CSSA) drugs. It employed a descriptive exploratory design using a web-based cross-sectional survey distributed through social media to gather data from pharmacists actively engaged in the pharmacy business in Pakistan. The survey aimed to evaluate the understanding, knowledge, and experiences of pharmacists in relation to CSSA drugs by reaching a broad spectrum of respondents. A total of 166 participants, primarily from the private sector, were involved, with experience averaging 11.19 years in the pharmacy business. The findings indicated significant loopholes in the pharmaceutical supply chain that contribute to the spread of CSSA drugs, with more than half of the respondents acknowledging a lack of training on pharmacy law and regulations. The study emphasized the need for improved training, infrastructure development, and a robust regulatory framework to secure the supply chain and reduce the prevalence of CSSA drugs.

Featured Image

Why is it important?

This study is important as it addresses the critical issue of counterfeit, substandard, spurious, and adulterated (CSSA) drugs within the pharmaceutical supply chain, which poses significant risks to public health and safety. By identifying the existing loopholes and the lack of training in pharmacy law and regulations among distributors, the research emphasizes the need for improved regulatory frameworks and infrastructure development to curtail the spread of CSSA drugs. The findings underscore the importance of enhancing the awareness and competence of pharmacists and regulatory bodies, which is essential for ensuring the availability of quality medicines and protecting patients from potentially harmful drugs. These insights have direct implications for policy makers and healthcare professionals aiming to strengthen the integrity of pharmaceutical supply chains and improve public health outcomes. Key Takeaways: 1. Training Deficiency: The study reveals that more than half of the respondents (55.4%) have not received adequate training on pharmacy law and regulations, highlighting a significant gap that contributes to the proliferation of CSSA drugs. 2. Supply Chain Loopholes: Identified weaknesses within the pharmaceutical supply chain exacerbate the spread of CSSA drugs, emphasizing the need for a secure and transparent supply chain system bolstered by robust regulatory measures. 3. Role of Regulatory Initiatives: Initiatives by regional and national drug authorities, such as the establishment of the Provincial Drug Control Unit and revamping of Drug Testing Laboratories, are crucial steps in combating CSSA drugs; however, challenges remain due to financial constraints and the need for skilled human resources.